FDA approves Oculis application for MS relapse drug
Monday 16th November 2026 on 09:15 in
Iceland
Oculis Holding AG said the US Food and Drug Administration has approved its investigational new drug application for Privosegtor to treat acute multiple sclerosis relapses, mbl.is reported.
The approval follows feedback from the FDA’s Division of Neurology 2 before the application was submitted. The agency confirmed Oculis could refer to data from its existing IND application for Privosegtor in ophthalmology, the company said.
The FDA also supported Oculis’s proposed clinical development plan, which would include patients with MS who have optic neuritis and those experiencing other types of relapse, such as relapses that affect walking. The plan calls for the study’s primary endpoint to be assessed three months after treatment begins and for the same dose used in the PIONEER-1 study: 3 mg per kilogram daily for five days.
Optic neuritis is common both as an initial clinical symptom of MS and during acute relapses. Oculis described it as a pathophysiological model for acute demyelination that may be applicable to other acute MS relapses.